论文部分内容阅读
为了提高化疗药物的治疗指数和降低其毒性，制备了柔红霉素－人血清白蛋白微球（Ｄａｕ－ＨＡ－ＭＳ），绝大多数为单分散相微球，平均直径５６±１６μｍ，范围为２９─１９４μｍ，适用于导管动脉栓塞治疗。Ｄａｕ－ＨＡ～ＭＳ在生理盐水中能有效释放Ｄａｕ，但无爆发释放的缺点。释放的Ｄａｕ的光谱特性和体外细胞毒效应与原药相比无变化，表明Ｄａｕ通过微球制备仍保留原有的理化及生物学特性。实验表明经腹腔注射Ｄａｕ－ＨＡ－ＭＳ使３０％的Ｓ１８０腹水癌小鼠活存超过６个月，而肿瘤对照组及Ｄａｕ治疗肿瘤组均分别在２１ｄ和１４ｄ全部死亡，说明Ｄａｕ－ＨＡ－ＭＳ有较好的疗效及较低的毒性，提示Ｄａｕ－ＨＡ－ＭＳ有可能用于人肝癌的导管动脉栓塞治疗，有进一步研究的价值。
In order to improve the therapeutic index of chemotherapy drugs and reduce their toxicity, daunorubicin-human serum albumin microspheres (Dau-HA-MS) were prepared, the majority of them were monodisperse phase microspheres with an average diameter of 56 ± 16μm, 29 ─ 194μm, suitable for catheter arterial embolization. Dau-HA-MS can effectively release Dau in normal saline without the defect of burst release. The spectral characteristics of the released Dau and in vitro cytotoxicity showed no change compared with the original drug, indicating that Dau still retains the original physicochemical and biological properties by microsphere preparation. The results showed that 30% of S180 ascites tumor mice survived by intraperitoneal injection of Dau-HA-MS for more than 6 months, while the tumor control group and the Dau-treated tumor group all died on 21d and 14d respectively, indicating that Dau-HA-MS Have better curative effect and lower toxicity, suggesting that Dau-HA-MS may be used for the treatment of catheterization of human hepatocellular carcinoma and has further research value.